Core Insights - Medline has filed for an IPO aiming to raise up to $5.37 billion, which would value the company at approximately $55 billion, making it one of the largest public listings in the US for 2025 [1][4] - The company plans to list 179 million shares on the Nasdaq Global Select Market with an expected price range of $26 to $30 per share [1] Company Overview - Medline employs around 43,000 people and reported net revenues exceeding $25 billion in 2024, with net sales of $20.6 billion for the nine months ending September 27, 2025 [2] - The total addressable market for Medline is estimated to be around $375 billion annually, with the US market representing $175 billion of this opportunity [2] Market Opportunity - The company anticipates long-term growth in the US market driven by factors such as an aging population and increasing prevalence of chronic conditions, which are expected to elevate health expenditures [3] - Medline aims to achieve net sales growth through international expansion and ongoing innovation initiatives [3] IPO Context - If successful, Medline's IPO would be the largest in the medtech and broader healthcare sector for 2025, contrasting with the trend of AI-driven medtech IPOs this year [4] - Other notable AI medtech IPOs in 2025 include Beta Bionics and Kestra, raising $204 million and $235 million respectively [5]

Core Viewpoint - Medtronic presents a long-term investment opportunity despite recent stock performance challenges, with several factors supporting its potential for recovery and growth. Group 1: Business Overview - Medtronic has a market capitalization of approximately $110 billion and holds leading positions across various healthcare sectors, including cardiovascular products, neuroscience, medical surgery, and diabetes [2] - The company's global presence allows it to launch products in international markets while awaiting U.S. approvals, creating built-up demand upon U.S. market entry [4] Group 2: Dividend and Financial Metrics - Medtronic has a strong history of increasing dividends, having raised its dividend for 48 consecutive years, nearing Dividend King status [6] - The current dividend yield stands at 3.25%, significantly higher than the S&P 500's yield of 1.3% and the average healthcare stock yield of approximately 1.8%, indicating that the stock is historically cheap [8][9] - Traditional valuation metrics such as price-to-sales, price-to-earnings, and price-to-book ratios are currently below their five-year averages, suggesting an attractive pricing opportunity [10][11] Group 3: Growth Strategy - Medtronic is actively working to restore growth by focusing on research and development, introducing new products, and improving profit margins through the exit of less profitable business lines, particularly the spin-off of its diabetes division [14][15] - The management believes that the spin-off will be immediately accretive to earnings, as the diabetes division, despite its rapid growth, has lower margins compared to other segments [15]